March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Today’s safety scare with Lentiglobin calls into question the logic behind Bluebird’s planned business separation.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Evaluate Vantage's coverage of the virtual Ash 2020 congress.